FDA official notes possible cancer risk in diabetes drug Byetta

04/12/2010 | Bloomberg

An FDA official reported that injectable and once-weekly versions of diabetes drug Byetta "seem to give a similar signal" as cancer in mice that received Novo Nordisk's diabetes treatment Victoza. A representative of Eli Lilly and Co., which owns Byetta with Amylin Pharmaceuticals, said the once-weekly version's link to cancer risk "has not been established, but cannot be ruled out."

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC